- Home
- YCBD vs EPIX Comparison
YCBD vs EPIX Comparison
Compare YCBD & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YCBD
- EPIX
- Stock Information
- Founded
- YCBD 2015
- EPIX 2009
- Country
- YCBD United States
- EPIX Canada
- Employees
- YCBD N/A
- EPIX N/A
- Industry
- YCBD Biotechnology: Pharmaceutical Preparations
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- YCBD Health Care
- EPIX Health Care
- Exchange
- YCBD Nasdaq
- EPIX Nasdaq
- Market Cap
- YCBD 7.8M
- EPIX 9.0M
- IPO Year
- YCBD N/A
- EPIX N/A
- Fundamental
- Price
- YCBD $1.49
- EPIX $0.20
- Analyst Decision
- YCBD Strong Buy
- EPIX Hold
- Analyst Count
- YCBD 1
- EPIX 3
- Target Price
- YCBD $2.00
- EPIX $2.00
- AVG Volume (30 Days)
- YCBD 11.0M
- EPIX 3.0M
- Earning Date
- YCBD 08-14-2025
- EPIX 08-13-2025
- Dividend Yield
- YCBD N/A
- EPIX N/A
- EPS Growth
- YCBD N/A
- EPIX N/A
- EPS
- YCBD N/A
- EPIX N/A
- Revenue
- YCBD $19,026,064.00
- EPIX N/A
- Revenue This Year
- YCBD $0.37
- EPIX N/A
- Revenue Next Year
- YCBD $4.95
- EPIX N/A
- P/E Ratio
- YCBD N/A
- EPIX N/A
- Revenue Growth
- YCBD N/A
- EPIX N/A
- 52 Week Low
- YCBD $0.59
- EPIX $0.18
- 52 Week High
- YCBD $6.54
- EPIX $6.45
- Technical
- Relative Strength Index (RSI)
- YCBD 72.63
- EPIX 12.03
- Support Level
- YCBD $0.60
- EPIX $0.20
- Resistance Level
- YCBD $1.94
- EPIX $0.22
- Average True Range (ATR)
- YCBD 0.23
- EPIX 0.02
- MACD
- YCBD 0.07
- EPIX 0.06
- Stochastic Oscillator
- YCBD 64.18
- EPIX 40.00
About YCBD cbdMD Inc.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.